AR035131A1 - Composiciones topicas y metodos para el tratamiento del dolor - Google Patents

Composiciones topicas y metodos para el tratamiento del dolor

Info

Publication number
AR035131A1
AR035131A1 ARP020103069A ARP020103069A AR035131A1 AR 035131 A1 AR035131 A1 AR 035131A1 AR P020103069 A ARP020103069 A AR P020103069A AR P020103069 A ARP020103069 A AR P020103069A AR 035131 A1 AR035131 A1 AR 035131A1
Authority
AR
Argentina
Prior art keywords
methods
topical compositions
pain
pain treatment
compositions
Prior art date
Application number
ARP020103069A
Other languages
English (en)
Original Assignee
Epicept Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epicept Corp filed Critical Epicept Corp
Publication of AR035131A1 publication Critical patent/AR035131A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/113—Multiple emulsions, e.g. oil-in-water-in-oil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Dispersion Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composiciones tópicas y métodos para tratar el dolor. La presente provee emulsiones aceite en agua que comprenden un antidepresivo, un antagonista del receptor del NMDA, un componente lipofílico, agua y un tensioactivo. Las composiciones inducen un efecto anestésico local cuando se administran en forma tópica a la piel intacta, tratando o previniendo por ello el dolor, por ejemplo el dolor neuropático.
ARP020103069A 2001-08-17 2002-08-14 Composiciones topicas y metodos para el tratamiento del dolor AR035131A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/931,293 US6638981B2 (en) 2001-08-17 2001-08-17 Topical compositions and methods for treating pain

Publications (1)

Publication Number Publication Date
AR035131A1 true AR035131A1 (es) 2004-04-14

Family

ID=25460543

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020103069A AR035131A1 (es) 2001-08-17 2002-08-14 Composiciones topicas y metodos para el tratamiento del dolor

Country Status (13)

Country Link
US (2) US6638981B2 (es)
EP (1) EP1438020A4 (es)
JP (1) JP2005501844A (es)
KR (1) KR20040053112A (es)
CN (1) CN100496472C (es)
AR (1) AR035131A1 (es)
AU (1) AU2002335635B2 (es)
CA (1) CA2457780C (es)
HK (1) HK1089364A1 (es)
IL (2) IL160388A0 (es)
MX (1) MXPA04001368A (es)
NZ (1) NZ531547A (es)
WO (1) WO2003015699A2 (es)

Families Citing this family (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10179159B2 (en) * 1999-10-22 2019-01-15 Scott Wepfer Topical anesthetic formulation
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US20020091129A1 (en) * 2000-11-20 2002-07-11 Mitradev Boolell Treatment of premature ejaculation
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
US20050013853A1 (en) * 2000-11-29 2005-01-20 Irit Gil-Ad Anti-proliferative drugs
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
EP1482921A1 (en) * 2002-02-12 2004-12-08 Cypress Bioscience, Inc. Methods of treating attention deficit/hyperactivity disorder (adhd)
US20040033255A1 (en) * 2002-06-10 2004-02-19 Baker Carl J. Transdermal delivery device disposal system
US7645462B2 (en) * 2002-08-27 2010-01-12 3T Herbtech, Inc. Acupoint patch
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
EP1558231A4 (en) * 2002-10-03 2010-09-08 Cypress Bioscience Inc DOSAGE CLIMBING AND FRICTIONAL DAILY DOSE OF ANTIDEPRESSANTS TO TREAT NEUROLOGICAL DISORDERS
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US10117812B2 (en) * 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
BR0314916A (pt) 2002-10-25 2005-08-16 Foamix Ltd Espuma farmacêutica e cosmética
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US20040138204A1 (en) * 2002-10-30 2004-07-15 Harrington James Frederick Compositions and methods for pain reduction
DK1567164T3 (da) 2002-11-26 2009-05-18 Alexza Pharmaceuticals Inc Anvendelse af loxapin til fremstilling af et lægemiddel til behandling af smerte
ES2535045T3 (es) 2003-04-10 2015-05-04 Vanderbilt Royalty Sub L.P. Usos y composiciones para administración de capsaicina
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
EP1625336B9 (en) 2003-05-21 2012-03-21 Alexza Pharmaceuticals, Inc. Use of a layer of solid fuel, method for producing such a layer and associated heating unit
US20050095277A1 (en) * 2003-06-25 2005-05-05 Binnur Ozturk Neuropathy cream
US20040265364A1 (en) * 2003-06-25 2004-12-30 Binnur Ozturk Neuropathy cream
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
DE10338174A1 (de) * 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
ES2541488T3 (es) * 2003-08-25 2015-07-21 Foamix Pharmaceuticals Ltd. Espuma farmacéutica penetrante
US20060148783A1 (en) * 2003-11-10 2006-07-06 Lundeen James E Method and medicine for treating gastrointestinal disorder including fecal incontinence
US20060148781A1 (en) * 2003-11-10 2006-07-06 Lundeen James E Method and medicine for treating gastrointestinal disorder in a non-human mammal
US20050113365A1 (en) * 2003-11-10 2005-05-26 Sir Isaac Newton Enterprises Llc Method and medicine for treating gastrointestinal disorder including irritable bowel syndrome
US8334263B2 (en) * 2003-12-16 2012-12-18 Raymond Nadeson Analgesic methods and compositions
AU2004298288B2 (en) * 2003-12-16 2011-06-30 Relevare Aust. Pty Ltd Methods and compositions
WO2005082054A2 (en) * 2004-02-26 2005-09-09 Sosei Co., Ltd. Combinations for the treatment of fungal infections
US20060063802A1 (en) 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US8268866B2 (en) * 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US9072662B2 (en) 2004-03-29 2015-07-07 Auris Medical Ag Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US20080241082A1 (en) * 2004-04-05 2008-10-02 Lonza Inc. Method for the Preparation of Cosmetic Emulsion
CA2562078A1 (en) * 2004-04-08 2005-10-27 Vela Pharmaceuticals, Inc. Compositions and methods for treatment of neuropathic pain, fibromyalgia and chronic fatigue syndrome
MXPA06012563A (es) * 2004-04-29 2007-03-21 Caldwell Galer Inc Composiciones topicas de metadona y metodos para usar las mismas.
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
US7666914B2 (en) * 2004-06-03 2010-02-23 Richlin David M Topical preparation and method for transdermal delivery and localization of therapeutic agents
WO2006022611A2 (en) * 2004-06-26 2006-03-02 Binnur Ozturk Neuropathy cream
US7704522B2 (en) * 2004-09-08 2010-04-27 Clyde Morgan Topical medicament
US7740875B2 (en) * 2004-10-08 2010-06-22 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US20060078580A1 (en) * 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
WO2006051818A1 (ja) * 2004-11-10 2006-05-18 Hisamitsu Pharmaceutical Co., Inc. 外用製剤及び貼付剤
DE102005004343A1 (de) * 2005-01-25 2006-08-10 Eberhard-Karls-Universität Tübingen Universitätsklinikum Behandlung von Phantomphänomenen
EP1856075A1 (en) * 2005-01-25 2007-11-21 Epix Delaware, Inc. Substituted arylamine compounds and their use as 5-ht6 modulators
EP1858495A2 (en) * 2005-02-14 2007-11-28 Neurogesx, Inc. Device for delivery of trpv1 agonists
EP1861104A4 (en) * 2005-03-04 2011-12-14 Neurosystec Corp IMPROVED GACYCLIDINE FORMULATIONS
ES2696598T3 (es) * 2005-03-21 2019-01-17 Univ Columbia Compuestos de balanol para su uso en el tratamiento de dolor
US20060223788A1 (en) * 2005-03-29 2006-10-05 Cathcart Clifton H Analgesic composition for topical use
CA2602832A1 (en) * 2005-03-30 2006-10-05 Keith R. Bley Low-concentration capsaicin patch and methods for treating neuropathic pain
US20060223786A1 (en) * 2005-04-01 2006-10-05 Smith David J Transdermal pain control method and device
US20070027152A1 (en) * 2005-07-27 2007-02-01 Clark Kathleen L Topical anti-pruritic compositions and methods of action of same
AU2005337107B2 (en) * 2005-09-28 2012-05-24 Auris Medical Ag Pharmaceutical compositions for the treatment of inner ear disorders
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
JP2009516751A (ja) * 2005-11-21 2009-04-23 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティー・オブ・アラバマ・フォー・アンド・オン・ビハーフ・オブ・ザ・ユニバーシティー・オブ・アラバマ 神経保護のための小分子化合物を使用する方法
US20070148194A1 (en) * 2005-11-29 2007-06-28 Amiji Mansoor M Novel nanoemulsion formulations
WO2007088473A2 (en) * 2006-02-03 2007-08-09 Neurocure Ltd Treatment and prevention of depression with pain, depression secondary to pain, and of neuropathic pain
EP1998742A2 (en) * 2006-03-08 2008-12-10 Nuviance, INC. Transdermal drug delivery compositions and topical compositions for application on the skin
WO2007118605A1 (en) * 2006-04-18 2007-10-25 Dsm Ip Assets B.V. Cosmetic compositions comprising salicylic acid and ascorbic acid
US20070248657A1 (en) * 2006-04-25 2007-10-25 Smith David J Multi-compartment transdermal pain control device
US20070270413A1 (en) * 2006-05-22 2007-11-22 N.V. Organon Mirtazapine for the treatment of neuropathic pain
TWI392670B (zh) * 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
AU2007269440A1 (en) * 2006-06-30 2008-01-10 Nucryst Pharmaceuticals Corp. Metal-containing formulations and methods of use
PT2117521E (pt) 2006-11-03 2012-09-10 Durect Corp Sistemas de administração transdérmica que compreendem bupivacaína
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
WO2008085711A1 (en) * 2007-01-03 2008-07-17 Konova Synergy of sodium channel blockers and calcium channel blockers
US20080216828A1 (en) 2007-03-09 2008-09-11 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
WO2008139484A2 (en) * 2007-05-16 2008-11-20 R. L. Fine Chem New process for the synthesis of loferpramine maleate: a stable salt of loferpramine
US9511016B2 (en) * 2007-06-12 2016-12-06 Epicentrx, Inc. Topical composition for treating pain
EP2175886A1 (en) * 2007-06-28 2010-04-21 CNSBio Pty Ltd Combination methods and compositions for treatment of neuropathic pain
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US20090130048A1 (en) * 2007-11-19 2009-05-21 Oronsky Bryan Todd Topical Composition for Treating Pain
US8784872B2 (en) 2007-11-19 2014-07-22 Comgenrx, Inc. Formulation for decreasing tobacco, alcohol, drug or food consumption
WO2009069006A2 (en) 2007-11-30 2009-06-04 Foamix Ltd. Foam containing benzoyl peroxide
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
WO2010041141A2 (en) 2008-10-07 2010-04-15 Foamix Ltd. Oil-based foamable carriers and formulations
EP2242476A2 (en) 2008-01-14 2010-10-27 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
ITMI20080316A1 (it) * 2008-02-27 2009-08-28 Aboca Spa Impiego di estratti di hypericum perforatum nel trattamento del dolore neuropatico
WO2009158667A2 (en) * 2008-06-27 2009-12-30 Comgenrx, Inc. Povidone compositions for wound healing
CN102223791A (zh) 2008-09-27 2011-10-19 塔阿克斯有限公司 用于神经病变治疗的局部用制剂
US8198268B2 (en) * 2008-10-31 2012-06-12 Janssen Biotech, Inc. Tianeptine sulfate salt forms and methods of making and using the same
US20100221313A1 (en) * 2008-12-01 2010-09-02 Innovative Pharmaceuticals, Llc Transdermal reservoir patch
US8454877B2 (en) * 2009-04-03 2013-06-04 Pelican Products, Inc. Method and apparatus for molding an article
CA2760186C (en) 2009-04-28 2019-10-29 Foamix Ltd. Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
WO2011013008A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
CA2769625C (en) 2009-07-29 2017-04-11 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
CA2776471C (en) 2009-10-02 2019-02-12 Foamix Ltd. Surfactant-free, water-free, foamable compositions and breakable foams and their uses
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US8174881B2 (en) 2009-11-24 2012-05-08 Micron Technology, Inc. Techniques for reducing disturbance in a semiconductor device
CN102781442B (zh) * 2009-12-15 2016-02-17 儿童医院 使用奈福泮化合物治疗瘢痕和β-联蛋白介导的疾病的方法
DE102010024105A1 (de) 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
CN102858321A (zh) * 2010-06-18 2013-01-02 莫茨药物股份两合公司 用于局部使用1-氨基-烷基环己烷衍生物的凝胶制剂
CN101966151B (zh) * 2010-09-06 2011-11-09 海南美大制药有限公司 马来酸曲米帕明脂质体固体制剂
EA027290B1 (ru) 2011-03-04 2017-07-31 Грюненталь Гмбх Водная фармацевтическая композиция тапентадола для перорального введения
CA2850964C (en) * 2011-10-05 2021-02-02 Jennifer L. Sanders Methods and compositions for treating foot or hand pain
US9012486B2 (en) * 2011-11-14 2015-04-21 Alex Chervinsky Topical composition for pain relief
WO2013087090A1 (en) 2011-12-12 2013-06-20 Auris Medical Ag Treatment of tinnitus through modulation of chloride co-transporter nkcc1 in the auditory system
WO2013138520A1 (en) * 2012-03-13 2013-09-19 University Of Tennessee Research Foundation Composition and system for transdermal delivery
ES2484068B1 (es) * 2013-02-08 2015-04-16 Ana MÍNGUEZ MARTÍ Una composición farmacéutica que contiene ketamina y amitriptilina
WO2014165307A2 (en) * 2013-03-14 2014-10-09 The Regents Of The University Of California Modulation of k2p channels
US9597099B2 (en) 2013-07-29 2017-03-21 Covidien Lp Energy-based treatment methods for refractory gout
WO2015081007A1 (en) 2013-11-26 2015-06-04 Humco Holding Group, Inc. Transdermal silicone gel (silogel) compositions and methods of preparation
US11141452B2 (en) * 2014-02-24 2021-10-12 Arizona Board Of Regents On Behalf Of The University Of Arizona Bifunctional compounds for relief of pain comprising an opioid receptor agonist moiety and a NK1 receptor antagonist moiety and methods for treating pain
EP2946776A1 (de) * 2014-05-20 2015-11-25 LTS LOHMANN Therapie-Systeme AG Transdermales therapeutisches System zur Abgabe von Amitriptylin
US9012402B1 (en) 2014-06-11 2015-04-21 James Blanchard Gel for topical delivery of NSAIDs to provide relief of musculoskeletal pain and methods for its preparation
KR20170110083A (ko) 2014-12-23 2017-10-10 인털렉츄얼 프라퍼티 어쏘시에이츠, 엘엘씨 경피 투여를 위한 방법 및 제형
DK3273953T3 (en) 2015-03-27 2019-03-11 Gruenenthal Gmbh STABLE FORMULATION FOR PARENTERAL ADMINISTRATION OF TAPENTADOL
BR112017027750B8 (pt) * 2015-06-22 2022-08-09 Johnson & Johnson Consumer Inc Artigo de múltiplas camadas aplicado topicamente para fornecer um benefício cosmético e/ou terapêutico sobre a pele, método não-terapêutico para fornecer um benefício cosmético à pele e agente terapêutico
WO2017049158A1 (en) * 2015-09-16 2017-03-23 The Trustees Of Columbia University In The City Of New York Carboxylic diarylthiazepineamines as mu-opioid receptor agonists
US20180318279A1 (en) * 2015-10-23 2018-11-08 Rush University Medical Center Topical compositions providing pain relief and methods of use thereof
US10004734B2 (en) 2016-01-26 2018-06-26 Warren Scherer Compositions and methods for treating rebound erythema associated with topical alpha-adrenergic agonists
GB2564990A (en) * 2016-04-01 2019-01-30 Good Pharmaceutical Dev Company Llc Topical compositions for neuropathic pain
US10463699B2 (en) 2016-04-04 2019-11-05 Omeza LLC Fish oil topical composition
CN106243096B (zh) * 2016-07-29 2019-11-29 上海璃道医药科技有限公司 三环类药物的新用途
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
CA3037810A1 (en) 2016-09-23 2018-03-29 Grunenthal Gmbh Stable formulation for parenteral administration of tapentadol
EP3551182A1 (en) 2016-12-06 2019-10-16 Topical Innovations B.V. Topical pharmaceutical composition containing phenytoin and a (co -)an algesic for the treatment of chronic pain
FR3065371B1 (fr) * 2017-04-25 2021-05-21 Laboratoires Mayoly Spindler Composition pharmaceutique topique comprenant au moins de l'amitriptyline pour le traitement de douleurs neuropathiques peripheriques
US10821075B1 (en) 2017-07-12 2020-11-03 James Blanchard Compositions for topical application of a medicaments onto a mammalian body surface
DE102017215154A1 (de) * 2017-08-30 2019-02-28 Markus Bläss Zusammensetzung zur topischen Behandlung von nicht-Mikroorganismus-verursachten entzündlichen Haut- und Schleimhauterkrankungen
EP4324460A3 (en) 2017-09-15 2024-04-24 Dyve Biosciences, Inc. Sodium bicarbonate for use in the treatment of gout and related disorders
US10959975B1 (en) 2017-11-02 2021-03-30 The Tetra Corporation Antifungal composition, method of making composition, and method of using composition
US20190209472A1 (en) * 2017-12-04 2019-07-11 Sienna Biopharmaceuticals, Inc. Formulations for dermal delivery of polymer conjugates of indolocarbazole compounds with reduced exposure
WO2020188457A1 (en) * 2019-03-15 2020-09-24 Ftf Pharma Private Limited Solutions for oral dosage
US11752114B2 (en) * 2019-04-17 2023-09-12 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system
PL430531A1 (pl) * 2019-07-09 2021-01-11 Biotts Spółka Akcyjna Podłoże oraz kompozycja farmaceutyczna je zawierająca
FR3108841B1 (fr) * 2020-04-06 2023-11-03 Algotherapeutix Composition pharmaceutique topique sous forme de gel aqueux comprenant au moins de l’amitriptyline
EP3949956A1 (en) * 2020-08-06 2022-02-09 LTS Lohmann Therapie-Systeme AG Esketamine-suspension-tts
CN114225039A (zh) * 2021-12-29 2022-03-25 中国科学院深圳先进技术研究院 一种拮抗剂组合物及其在制备治疗睡眠障碍与精神疾病共患病的药物中的应用
CN115006346B (zh) * 2022-07-05 2023-11-21 湖南洞庭药业股份有限公司 精神疾病治疗剂的稳定化方法和包含阿米替林的组合物

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR79380B (es) 1982-09-28 1984-10-22 Johnson & Johnson Prod Inc
US4751087A (en) 1985-04-19 1988-06-14 Riker Laboratories, Inc. Transdermal nitroglycerin delivery system
US4615699A (en) 1985-05-03 1986-10-07 Alza Corporation Transdermal delivery system for delivering nitroglycerin at high transdermal fluxes
US4801586A (en) 1986-04-23 1989-01-31 Nelson Research & Development Co. Penetration enhancers for transdermal delivery of systemic agents
US4755535A (en) 1986-04-23 1988-07-05 Nelson Research & Development Co. Compositions comprising 1-substituted azacycloalkenes
US4808414A (en) 1986-09-29 1989-02-28 Nelson Research & Development Co. Amide penetration enhancers for transdermal delivery of systemic agents
US4920101A (en) 1987-09-30 1990-04-24 Nelson Research & Development Co. Compositions comprising 1-oxo- or thiohydrocarbyl substituted azacycloaklkanes
US4989607A (en) 1989-03-30 1991-02-05 Preston Keusch Highly conductive non-stringy adhesive hydrophilic gels and medical electrode assemblies manufactured therefrom
EP0424179A3 (en) 1989-10-20 1991-12-27 John William Olney Use of combined excitatory amino acid and cholinergic antagonists to prevent neurological deterioration
ATE220320T1 (de) 1990-03-02 2002-07-15 Oregon State Tri- und tetra-substituierte guanidine und deren verwendung als antagonisten von exzitatorischen aminosäuren
US5708035A (en) 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
WO1993007902A1 (en) * 1991-10-16 1993-04-29 Richardson-Vicks, Inc. Enhanced skin penetration system for improved topical delivery of drugs
WO1993010163A2 (en) 1991-11-12 1993-05-27 Nepera, Inc. Adhesive hydrogels having extended use lives and process for the preparation of same
CA2099233A1 (en) 1992-06-29 1993-12-30 Conrad P. Dorn Morpholine and thiomorpholine tachykinin receptor antagonists
US5922340A (en) 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
TW336932B (en) 1992-12-17 1998-07-21 Pfizer Amino-substituted pyrazoles
PL175831B1 (pl) 1992-12-17 1999-02-26 Pfizer Pochodna pirazolu
JP2895961B2 (ja) 1992-12-17 1999-05-31 フアイザー・インコーポレイテツド Ｃｒｆアンタゴニストとしてのピロロピリミジン
TW444018B (en) 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
KR100190730B1 (ko) 1992-12-17 1999-06-01 디. 제이. 우드, 스피겔 알렌 제이 부신피질 호르몬 유리인자(crf) 길항물질로서 치환된 피라졸
CA2115792C (en) * 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
EP0696320B1 (en) 1993-04-20 2002-09-25 Merck & Co., Inc. Human n-methyl-d-aspartate receptor subunits, nucleic acids encoding same and uses therefor
US5631373A (en) 1993-11-05 1997-05-20 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
DE69428913T2 (de) 1993-12-29 2002-05-29 Merck Sharp & Dohme Substituierte morpholinderivate und ihre verwendung als arzneimittel
EP0743855A1 (en) 1994-01-03 1996-11-27 Acea Pharmaceuticals, Inc. 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/nmda receptor
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
US5635204A (en) 1994-03-04 1997-06-03 Montefiore Medical Center Method for transdermal induction of anesthesia, analgesia or sedation
US5962477A (en) 1994-04-12 1999-10-05 Adolor Corporation Screening methods for cytokine inhibitors
DE69532039T2 (de) 1994-08-30 2004-07-08 Sankyo Co., Ltd. Isoxazole
US5476933A (en) 1994-11-16 1995-12-19 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Azepine synthesis via a diels-alder reaction
US5948389A (en) 1995-06-07 1999-09-07 El Khoury & Stein, Ltd. Method of enhancing the analgesic efficacy of locally and topically administered opioids and other local anesthetics
US6197830B1 (en) 1995-09-22 2001-03-06 Bruce M. Frome Method for achieving relief from sympathetically mediated pain
AU738304B2 (en) 1995-10-13 2001-09-13 Neurogen Corporation Certain pyrrolopyridine derivatives; novel CRF 1 specific ligands
IN184685B (es) 1996-02-14 2000-09-23 Nat Inst Immunology
US5688955A (en) 1996-03-08 1997-11-18 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
US5646151A (en) 1996-03-08 1997-07-08 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
US5763445A (en) 1996-03-08 1998-06-09 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
US5888494A (en) 1996-03-12 1999-03-30 Adolor Corporation Film-forming compositions of antihyperalgesic opiates and method of treating hyperalgesic and pruritic conditions therewith
US5667773A (en) 1996-03-12 1997-09-16 Adolor Corporation Film-forming compositions of antihyperalgesic opiates and method of treating hyperalgesic conditions therewith
US6025369A (en) 1996-05-03 2000-02-15 The Board Of Regents Of The University Nebraska N-methyl-D-aspartate (NMDA) receptor blockers for the prevention of atherosclerosis
US6191165B1 (en) 1996-05-31 2001-02-20 Allelix Neuroscience Inc. Pharmaceutical for treatment of neurological and neuropsychiatric disorders
US6191131B1 (en) 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
JP2001502300A (ja) 1996-09-16 2001-02-20 デュポン ファーマシューティカルズ カンパニー ピラジノン類およびトリアジノン類およびその誘導体類
US6117855A (en) 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
US5811078A (en) 1997-03-14 1998-09-22 Adolor Corporation Spray formulations of antihyperalgesic opiates and method of treating topical hyperalgesic conditions therewith
US5798093A (en) 1997-03-14 1998-08-25 Adolor Corporation Spray formulations of antihyperalgesic opiates and method of treating topical hyperalgesic conditions and pruritus therewith
US5817699A (en) 1997-05-30 1998-10-06 Flores; John A. Process for the preparation of ketamine ointment
US5783700A (en) 1997-07-03 1998-07-21 Nichols; Alfred C. Quinolic acid derivatives
US5760023A (en) 1997-07-14 1998-06-02 Adolor Corporation Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith
EP0996434A4 (en) 1997-07-14 2001-10-10 Adolor Corp ANTI-PRURITIC PHARMACEUTICAL COMPOSITIONS CONTAINING KAPPA RECEPTOR AGONISTS AND METHOD FOR TREATING PRURITUS USING THE SAME
US5849762A (en) 1997-07-14 1998-12-15 Adolor Corporation Peripherally acting anti-pruritic opiates
JP3393991B2 (ja) 1997-08-29 2003-04-07 タイコエレクトロニクスアンプ株式会社 カードコネクタ
DE19818924A1 (de) 1998-04-28 1999-11-04 Degussa Oberflächenmodifizierte Füllstoffe, Verfahren zu deren Herstellung sowie deren Verwendung
US6211171B1 (en) * 1998-05-19 2001-04-03 Dalhousie University Use of antidepressants for local analgesia
US6255302B1 (en) 1998-12-17 2001-07-03 American Home Products Corporation 1,4-piperazine derivatives
US6242448B1 (en) 1998-12-17 2001-06-05 American Home Products Corporation Trisubstituted-oxazole derivatives as serotonin ligands
FR2787450B1 (fr) 1998-12-18 2001-01-26 Adir Nouveaux derives spiroimidazoliniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2360683A1 (en) 1999-01-28 2000-08-03 Joseph P. Yevich Antidepressant heterocyclic compounds
GB9904163D0 (en) * 1999-02-23 1999-04-14 Bioglan Lab Ltd Pharmaceutical compositions
US6017961A (en) 1999-07-08 2000-01-25 Flores; John Anthony Ketamine and n-butyl-p-aminobezoate in PLO
CA2315815A1 (en) * 2000-07-19 2002-01-19 Peter R. Ford Topical pain relief composition and carrier

Also Published As

Publication number Publication date
EP1438020A4 (en) 2010-01-13
KR20040053112A (ko) 2004-06-23
CN100496472C (zh) 2009-06-10
US20030082214A1 (en) 2003-05-01
EP1438020A2 (en) 2004-07-21
HK1089364A1 (en) 2006-12-01
NZ531547A (en) 2006-08-31
WO2003015699A2 (en) 2003-02-27
AU2002335635B2 (en) 2008-06-05
MXPA04001368A (es) 2005-06-06
CN1747719A (zh) 2006-03-15
IL160388A0 (en) 2004-07-25
CA2457780A1 (en) 2003-02-27
US6638981B2 (en) 2003-10-28
IL160388A (en) 2010-02-17
CA2457780C (en) 2010-10-26
US20040076648A1 (en) 2004-04-22
JP2005501844A (ja) 2005-01-20
WO2003015699A3 (en) 2003-08-14

Similar Documents

Publication Publication Date Title
AR035131A1 (es) Composiciones topicas y metodos para el tratamiento del dolor
BRPI0410503A (pt) uso da ivermectina para a fabricação de uma composição farmacêutica tópica, composição tópica e uso da composição
BRPI0408153A (pt) formulações para administração transdérmica ou transmucosa de agente ativo, métodos de tratamento de distúrbios hormonais em indivìduo, uso de formulação e de melhorador de permeação e kit para tratamento de indivìduo
CY1107615T1 (el) Θεραπευτικοι συνδυασμοι αντιυπερτασικων και αντιαγγειογενετικων παραγοντων
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
BR0109850A (pt) Produto terapêutico de combinação, composição farmacêutica, uso de um produto terapêutico de combinação, e, método para o tratamento ou profilaxia de câncer de próstata
UY26130A1 (es) Compuestos para tratar la obesidad
BR0212019A (pt) Formas de dosagem, métodos para o tratamento da dor, métodos de preparação de uma forma de dosagem e métodos para impedir o abuso de uma forma de dosagem
PE20040895A1 (es) Formulacion de complejo de aripiprazol
CO2021000174A2 (es) Composiciones tópicas para el alivio del dolor
CL2012000348A1 (es) Metodo para tratar o reducir la gravedad de la osteoporosis u osteopenia en un paciente que comprende administrarle el compuesto n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-dihidro-4-oxoquinolina-3-carboxamida o una sal del mismo; composicion farmaceutica.
CR8850A (es) Composicion y metodo para tratar hemorroides y/o transtornos ano-rectales
CL2007001724A1 (es) Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1
CO2022013777A2 (es) Uso de agentes para el tratamiento de condiciones respiratorias
AR034900A1 (es) Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica
BRPI0415713A (pt) mio-inositol hexafosfato para uso tópico
CL2015001086A1 (es) Combinación farmacéutica para el tratamiento y/o quimiosensibilizacion de tumores refractarios a drogas anticancerigenas
AR112291A1 (es) Composición para su uso en la prevención y/o el tratamiento de la mucositis orogastrointestinal inducida por un tratamiento oncológico
BRPI0506630A (pt) composição de liberação controlada e método para administrar um medicamento aquoso transmucosal de liberação controlada
BRPI0519036A2 (pt) mÉtodo para o tratamento de um paciente acometido por uma doenÇa neuro-degenerativa; composiÇço farmacÊutica para tratar uma doenÇa neuro-degenerativa; e uso de um agonista 5-ht6 ou de um agonista 5-ht6
BR0107960A (pt) Tratamento de condições alérgicas e inflamatórias
CL2004001421A1 (es) Composicion farmaceutica que comprende un compuesto derivado de 1,4-dipiperidin-4-il-piperazina; y su uso para la prevencion y/o tratamiento del dolor.
BR0111051A (pt) Produto farmacêutico e dose farmacêutica diária para administração a um paciente, regime de dose prover um efeito anti-androgênico e um efeito anti-estrogênico em um paciente, uso de um composto e de tamoxifeno ou de um sal ou solvato farmaceuticamente aceitável destes, e, método para prover um efeito anti-androgênico em um paciente
DE60019947D1 (de) Vorbeugung von kolorektalkrebs
PA8549401A1 (es) Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido

Legal Events

Date Code Title Description
FB Suspension of granting procedure